Plasma concentrations of somatostatin
Somatostatin-like immunoreactivity (SLI) is found in the portal and peripheral blood of animals (Pimstone et al., 1978; Schusdziarra et al., 1978; Wasada et al., 1980; Patel et al., 1981) and humans (Pimstone et al., 1978; Kronheim et al., 1978; Saito, 1980; Wass et al., 1980; Mackes et al., 1981; Vinik et al., 1981) Gel filtration chromatography Figure2depicts the gel chromatographic profiles of SLI in paired plasma extracts from uremic patients before and after hemodialysis. Two peaks, coeluting with SS-28 and SS-14markers, respectively, were present in both samples. The major peak (SS-28LI) was not affected by treatment with PEG, indicating that this peak is independent of non-specific interference substances. The area under the curve of the SS-28LI peak was3-fold larger than that for SS-14LI, when estimated by the reference to the SS-14standard. Consequently, SS-28LI constitutes approximately75% of the circulating somatostatin, on a molar basis. The ratio of SS-28LI/SS-14LI remained unchanged by hemodialysis. between these studies and ours is not obvious at the present time. It may depend on the subject group studied, or, even more, the assay method employed.
The most intriguing observation of this study is that plasma SLI in uremic patients consists mainly (75%) of the SS-28LI component.
This finding is unique if consideration is given to the fact that the molar ratio of plasma SS-14vs SS-28in healthy subjects is69%: 31% (Polonsky et al., 1983) and71%: 29% (Miyazaki et al., 1986) , respectively.
It has been reported that the extraction rate of SS-28by both kidney and liver is significantly lower than that of SS-14in dogs (Polonsky et al., 1982) . Thus, we can suppose that such is the case in uremic patients, and somatostatin, especially SS-28 component, may easily accumulate in their plasma, even under maintenance hemodialysis.
The reason why plasma SLI levels were raised after hemodialysis is unclear.
Probably the hemoconcentration may be one explanation of this finding, because there was no change in the plasma concentration ratio of SS-14vs SS-28before and after hemodialysis.
The physiologic implication of these observations remains to be elucidated. In view of the findings that somatostatin has a broad spectrum of inhibitory actions on the central and peripheral nervous system, endocrine and digestive organs and that SS-28 is more active than SS-14in some biological systems (Polonsky et al., 1982) , elevated plasma levels of somatostatin may be partly responsible for the uremic symptoms and pathophysiology of chronic renal failure.
